Who is sponsoring NCT03865394?

NCT03865394 is sponsored by Medical University of Warsaw.

What condition does NCT03865394 study?

NCT03865394 studies Diabetic Foot Ulcer.

Is NCT03865394 still recruiting?

NCT03865394 is currently completed. Last updated 14 October 2021.

Last reviewed 2021-10-14 · How we verify

NCT03865394: 1ABC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Chronic Wounds in Diabetic Foot Syndrome With Allogeneic Adipose Derived Mesenchymal Stem Cells

Completed Phase 1, PHASE2 Last updated 14 October 2021

What this trial tests

Phase 1, PHASE2 trial testing Application of allogeneic ADSC stem cells in fibrin gel in Diabetic Foot Ulcer in 46 participants. Completed in 30 September 2021.

Timeline

1 July 2019

Primary endpoint
31 March 2021

30 September 2021

Quick facts

Lead sponsor	Medical University of Warsaw
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	46
Start date	1 July 2019
Primary completion	31 March 2021
Estimated completion	30 September 2021
Sites	1 location across Poland

Drugs / interventions tested

Application of allogeneic ADSC stem cells in fibrin gel — full drug profile →
Standard care in diabetic foot ulcer

Conditions studied

Diabetic Foot Ulcer — all drugs for Diabetic Foot Ulcer →

Sponsor

Medical University of Warsaw

Who can join

18 and older, any sex, with Diabetic Foot Ulcer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate efficiency of applying of adipose-derived mesenchymal stem cells (ADSC) in treatment of chronic wounds in diabetic foot syndrome.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Diabetic Wound-Healing Science.
Burgess JL, Wyant WA, Abdo Abujamra B, Kirsner RS, et al · · 2021 · cited 447× · PMID 34684109 · DOI 10.3390/medicina57101072
Fat Therapeutics: The Clinical Capacity of Adipose-Derived Stem Cells and Exosomes for Human Disease and Tissue Regeneration.
Shukla L, Yuan Y, Shayan R, Greening DW, et al · · 2020 · cited 129× · PMID 32194404 · DOI 10.3389/fphar.2020.00158
Adipose Tissue-Derived Mesenchymal Stem/Stromal Cells and Their Contribution to Angiogenic Processes in Tissue Regeneration.
Krawczenko A, Klimczak A. · · 2022 · cited 64× · PMID 35269568 · DOI 10.3390/ijms23052425
Adipose-derived stromal cells for nonhealing wounds: Emerging opportunities and challenges.
Deptuła M, Brzezicka A, Skoniecka A, Zieliński J, et al · · 2021 · cited 38× · PMID 33522005 · DOI 10.1002/med.21789
Innovative Functional Biomaterials as Therapeutic Wound Dressings for Chronic Diabetic Foot Ulcers.
Da Silva J, Leal EC, Carvalho E, Silva EA. · · 2023 · cited 27× · PMID 37373045 · DOI 10.3390/ijms24129900
Scaffold-based delivery of mesenchymal stromal cells to diabetic wounds.
Du S, Zeugolis DI, O'Brien T. · · 2022 · cited 27× · PMID 35987712 · DOI 10.1186/s13287-022-03115-4
Adipose-Derived Stromal Cells for Chronic Wounds: Scientific Evidence and Roadmap Toward Clinical Practice.
Brembilla NC, Vuagnat H, Boehncke WH, Krause KH, et al · · 2023 · cited 20× · PMID 36571216 · DOI 10.1093/stcltm/szac081
Sources, Characteristics, and Therapeutic Applications of Mesenchymal Cells in Tissue Engineering.
Gonzalez-Vilchis RA, Piedra-Ramirez A, Patiño-Morales CC, Sanchez-Gomez C, et al · · 2022 · cited 19× · PMID 35092596 · DOI 10.1007/s13770-021-00417-1

Verify or expand the search:

Other recruiting trials for Diabetic Foot Ulcer

Currently open trials in the same condition.

NCT07161830 — Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers · NA · recruiting
NCT07396376 — Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers · Phase 1, PHASE2 · recruiting
NCT07291817 — Intermittent Negative Pressure for Patients With Diabetic Foot Ulcers (INPRESS) Study · NA · recruiting
NCT07209358 — EDX110 Randomized Control Trial for Treatment of DFUs · NA · recruiting
NCT06938685 — Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers · NA · recruiting

Other Medical University of Warsaw trials

Trials by the same sponsor.

NCT07515768 — TAVI Without On-Site Cardiac Surgery in Poland: A Randomized Multicenter Trial Protocol · NA · not yet recruiting
NCT07511907 — Routine Intraoperative White Test for Bile Leak Detection in Liver Resection · NA · not yet recruiting
NCT07498660 — PRP Injection Into the Sacroiliac Joint After Ipsilateral THA: Effects on Early Recovery and Function (SIJ-THA Randomize · NA · not yet recruiting
NCT07398898 — Use of Augmented Reality Glasses and Noise-Cancelling Headphones to Reduce Dental Anxiety in Adult Patients · NA · recruiting
NCT07237204 — 15 vs 45 Minute Pringle Maneuver in Liver Cancer Resection: Randomized Noninferiority Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03865394 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Warsaw
Last refreshed: 14 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03865394.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing